{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:24:15Z","timestamp":1781241855356,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.chest.2017.09.042","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T15:00:22Z","timestamp":1507820422000},"page":"23-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Higher Priced Older Pharmaceuticals"],"prefix":"10.1016","volume":"153","author":[{"given":"Richard S.","family":"Irwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Manaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Metersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Otulana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norine A.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2017.09.042_bib1","unstructured":"ASPE Issue Brief. Observations on trends in prescription drug spending March 8, 2016. Available at: https:\/\/aspe.hhs.gov\/system\/files\/pdf\/187586\/Drugspending.pdf. Accessed September 11, 2017."},{"issue":"16","key":"10.1016\/j.chest.2017.09.042_bib2","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jama.2014.13235","article-title":"Indication-specific pricing for cancer drugs","volume":"312","author":"Bach","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.chest.2017.09.042_bib3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.chest.2015.12.020","article-title":"Finding common ground: professionalism and Acthar prescribing practices","volume":"149","author":"Liss","year":"2016","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2017.09.042_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/jama.2016.5998","article-title":"Implications of proposed Medicare reforms to counteract high cancer drug prices","volume":"316","author":"Mailankody","year":"2016","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.chest.2017.09.042_bib5","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1056\/NEJMp1601559","article-title":"Essential medicines in the United States\u2013why access is diminishing","volume":"374","author":"Alpern","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2017.09.042_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nbt0315-217","article-title":"$1-million price tag set for Glybera gene therapy","volume":"33","author":"Morrison","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"9","key":"10.1016\/j.chest.2017.09.042_bib7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nbt.3003","article-title":"The special case of gene therapy pricing","volume":"32","author":"Brennan","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.chest.2017.09.042_bib8","unstructured":"Aetna. Available at: http:\/\/www.aetna.com\/cpb\/medical\/data\/700_799\/0762.html. Accessed November 30, 2016."},{"issue":"5","key":"10.1016\/j.chest.2017.09.042_bib9","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.chest.2015.12.007","article-title":"Fractional exhaled nitric oxide: inflamed coverage achieves remission","volume":"149","author":"Manaker","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2017.09.042_bib10","first-page":"371","article-title":"The effects of adrenocorticotropic hormone (ACTH) and cortisone on sarcoidosis","volume":"91","author":"Shulman","year":"1952","journal-title":"Bull Johns Hopkins Hosp"},{"key":"10.1016\/j.chest.2017.09.042_bib11","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1100\/tsw.2010.173","article-title":"The melanocortin system in control of inflammation","volume":"10","author":"Catania","year":"2010","journal-title":"ScientificWorldJournal"},{"issue":"5","key":"10.1016\/j.chest.2017.09.042_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/milmed\/148.5.419","article-title":"Improvement with corticotropin of relapsing central nervous system sarcoidosis during prednisone therapy: case report","volume":"148","author":"McGuire","year":"1983","journal-title":"Mil Med"},{"key":"10.1016\/j.chest.2017.09.042_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2015.11.007","article-title":"A\u00a0retrospective pilot study examining the use of Acthar gel in sarcoidosis patients","volume":"110","author":"Baughman","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2017.09.042_bib14","unstructured":"US National Institutes of Health. ClinicalTrails.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/results?term=acth+and+sarcoidosis&Search=Search. Accessed November 20,\u00a02016."},{"issue":"8","key":"10.1016\/j.chest.2017.09.042_bib15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","article-title":"Sarcoidosis in America. Analysis based on health care use","volume":"13","author":"Baughman","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.chest.2017.09.042_bib16","first-page":"56","article-title":"Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force","volume":"28","author":"Baughman","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"10.1016\/j.chest.2017.09.042_bib17","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"10.1016\/j.chest.2017.09.042_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2010.10.020","article-title":"Costs of asthma in the United States: 2002-2007","volume":"127","author":"Barnett","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.chest.2017.09.042_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.clinthera.2017.01.025","article-title":"Health care utilization and direct costs in mild, moderate, and severe adult asthma: a descriptive study using the 2014 South Korean Health Insurance Database","volume":"39","author":"Lee","year":"2017","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.chest.2017.09.042_bib20","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S2213-2600(15)00199-X","article-title":"New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches","volume":"3","author":"Baughman","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2017.09.042_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrneph.2011.190","article-title":"The renaissance of corticotropin therapy in proteinuric nephropathies","volume":"8","author":"Gong","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.chest.2017.09.042_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/1756285613518599","article-title":"Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis","volume":"7","author":"Berkovich","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1016\/j.chest.2017.09.042_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00408-017-9994-4","article-title":"Repository corticotropin for chronic pulmonary sarcoidosis","volume":"195","author":"Baughman","year":"2017","journal-title":"Lung"},{"issue":"3","key":"10.1016\/j.chest.2017.09.042_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1183\/09031936.00226911","article-title":"Global burden of chronic pulmonary aspergillosis complicating sarcoidosis","volume":"41","author":"Denning","year":"2013","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.chest.2017.09.042_bib25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2017.09.042_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2017.09.042_bib27","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"Sweiss","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2017.09.042_bib28","unstructured":"CMS.Gov. NHE fact sheet; NHE Tables, Table\u00a02. https:\/\/www.cms.gov\/research-statistics-data-and-systems\/statistics-trends-and-reports\/nationalhealthexpenddata\/nhe-fact-sheet.html. Accessed March 1,\u00a02017."},{"issue":"2","key":"10.1016\/j.chest.2017.09.042_bib29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1189\/jlb.0706426","article-title":"The melanocortin system in leukocyte biology","volume":"81","author":"Catania","year":"2007","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.chest.2017.09.042_bib30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1749-6632.2003.tb03172.x","article-title":"New insights into the functions of alpha-MSH and related peptides in the immune system","volume":"994","author":"Luger","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.chest.2017.09.042_bib31","series-title":"Clinical practice guidelines we can trust","year":"2011"},{"issue":"3","key":"10.1016\/j.chest.2017.09.042_bib32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.7326\/0003-4819-153-3-201008030-00010","article-title":"The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods","volume":"153","author":"Qaseem","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.chest.2017.09.042_bib33","series-title":"The healthcare imperative: lowering costs and improving outcomes \u2013 workshop series summary","year":"2011"},{"key":"10.1016\/j.chest.2017.09.042_bib34","unstructured":"American College of Physicians. High value care. https:\/\/www.acponline.org\/clinical-information\/high-value-care. Accessed November 30,\u00a02016."},{"key":"10.1016\/j.chest.2017.09.042_bib35","unstructured":"ABIM Foundation. Choosing wisely. http:\/\/www.choosingwisely.org\/. Accessed November 30,\u00a02016."},{"issue":"1","key":"10.1016\/j.chest.2017.09.042_bib36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7326\/M15-2768","article-title":"Stemming the escalating cost of prescription drugs: a position paper of the American College of Physicians","volume":"165","author":"Daniel","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.chest.2017.09.042_bib37","unstructured":"National Coalition on Health Care. Campaign for sustainable Rx pricing. http:\/\/www.csrxp.org\/. Accessed November 30,\u00a02016."},{"issue":"1 part 2","key":"10.1016\/j.chest.2017.09.042_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-156-1-201201031-00001","article-title":"American College of Physicians Ethics Manual: sixth edition","volume":"156","author":"Snyder","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.chest.2017.09.042_bib39","unstructured":"Available at: http:\/\/www.usatoday.com\/story\/money\/business\/2016\/08\/22\/two-senators-urge-scrutiny-epipen-price-boost\/89129620\/. USA Today. Accessed February 9,\u00a02017."},{"key":"10.1016\/j.chest.2017.09.042_bib40","unstructured":"Centers for Disease Control and Prevention. Strategies used by adults to reduce their prescription drug costs: United States 2013. https:\/\/www.cdc.gov\/nchs\/fastats\/health-expenditures.htm. Accessed November 30,\u00a02016."},{"key":"10.1016\/j.chest.2017.09.042_bib41","unstructured":"Rockoff J, Silverman E. Wall Street Journal. April 26, 2015. http:\/\/www.wsj.com\/articles\/pharmaceutical-companies-buy-rivals-drugs-then-jack-up-the-prices-1430096431. Accessed November 30\u00a02016."},{"key":"10.1016\/j.chest.2017.09.042_bib42","unstructured":"Crowe K. Tuberculosis drug price jumps 2,000%, shocks doctors. CBC News. September 21, 2015. http:\/\/www.cbc.ca\/news\/health\/tb-drug-price-cycloserine-1.3237868. Accessed November 30 2016."},{"issue":"5","key":"10.1016\/j.chest.2017.09.042_bib43","first-page":"250","article-title":"H.P. Acthar gel and cosyntropin review: clinical and financial implications","volume":"34","author":"Gettig","year":"2009","journal-title":"P\u00a0T"},{"issue":"2","key":"10.1016\/j.chest.2017.09.042_bib44","first-page":"143","article-title":"Paying for on-patent pharmaceuticals: limit prices and the emerging role of a pay for outcomes approach","volume":"39","author":"Fuller","year":"2016","journal-title":"J\u00a0Ambul Care Manage"},{"issue":"2","key":"10.1016\/j.chest.2017.09.042_bib45","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/COC.0000000000000251","article-title":"The Orphan Drug Act: restoring the mission to rare diseases","volume":"39","author":"Daniel","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.chest.2017.09.042_bib46","series-title":"Principles of Biomedical Ethics","author":"Beauchamp","year":"2008"},{"issue":"4","key":"10.1016\/j.chest.2017.09.042_bib47","doi-asserted-by":"crossref","first-page":"577","DOI":"10.5840\/beq200515440","article-title":"The corporate social responsibility of the pharmaceutical industry: idealism without illusion and realism without resignation","volume":"15","author":"Leisinger","year":"2005","journal-title":"Bus Ethics Q"},{"issue":"4","key":"10.1016\/j.chest.2017.09.042_bib48","doi-asserted-by":"crossref","first-page":"ofv179","DOI":"10.1093\/ofid\/ofv179","article-title":"Regulatory solutions to the problem of high generic drug costs","volume":"2","author":"Luo","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.chest.2017.09.042_bib49","series-title":"In Search of Equity","first-page":"1","article-title":"Health care needs and distributive justice","author":"Daniels","year":"1983"},{"issue":"1 suppl","key":"10.1016\/j.chest.2017.09.042_bib50","doi-asserted-by":"crossref","first-page":"73S","DOI":"10.1378\/chest.130.1_suppl.73S","article-title":"Patient-focused care: using the right tools","volume":"130","author":"Irwin","year":"2006","journal-title":"Chest"},{"issue":"25","key":"10.1016\/j.chest.2017.09.042_bib51","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","article-title":"Randomized, controlled trials, observational studies, and the hierarchy of research designs","volume":"342","author":"Concato","year":"2000","journal-title":"N\u00a0Engl J Med"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369217328805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369217328805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:01:30Z","timestamp":1757923290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369217328805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0012369217328805"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2017.09.042","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Higher Priced Older Pharmaceuticals","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2017.09.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}